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Abstract 
This study aims to contribute to estimating economic value of a patent/patent application for 
Biotechnology companies. To be able to perform a solid portfolio management of patents 
and patent applications, it is necessary to obtain an approximate economic value of 
patent/project in question. In this manner, this study seeks to answer the questions of how 
the value evolves throughout the filing process, what the value determinants of a patent are 
and how they affect the value of patent/patent application during filing process. After 
selecting major value determinants of innovation/patent by observing the interaction between 
the value determinants and patenting process, a questionnaire was prepared and a survey was 
carried out with participation of biotechnology companies. Based on the responses to the 
questionnaire, a proper mathematical model was attempted to be developed in order to use 
for further estimations on patent value.  
Keywords: Intellectual property; Patent; Patent portfolio; value of patent; value determinant 
of patent 
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1. Backgroud 
Intellectual property (IP) is a term referring to a number of different types of innovations of 
the mind; intellectual properties can be protected in accordance with their forms in different 
ways (Raysman, 1999). There are several forms of intellectual property rights (IPR) such as 
trademarks, trade secrets, industrial design rights, utility model, patents and copyrights. The 
most common and potent form of IPR is patent. Patent is the right to exclude the other 
parties from making, using, or selling the invention or technology as defined in the claims of 
the patent during its lifetime.  After a patent is granted by the patent office, lifetime of the 
patent is around 20 years (Zimmerer et al., 2008). 
Patent provides financial incentive to innovative companies. In this way, technology 
producing companies are encouraged for further research and development. For instance, if 
pharmaceutical industry is considered, patent of an effective medication can generate high 
income to the patent owner (van Triest and Vis, 2007). Intellectual property in the form of 
patentable technology, legally protectable designs and trademarks, and copyrights have 
increasingly become the most important assets, not only for many of the world‟s largest 
companies, but also for small and medium enterprises (SMEs) (EPO, 2009). In this sense, 
patents can be viewed not only as a legal document protecting a technical solution to a 
problem, but as a basis for commercial opportunities – an option (Office, 2010). 
 
Since biotechnology is a highly innovative field, the most preferred way of protecting the 
technology has become patents held by biotechnology companies. The number of patents 
granted in biotechnology ascended 15% a year at the United States Patent and Trademark 
Office (USPTO) from 1990 to 2000, and 10.5% at the EPO, against a 5% a year overall 
increase in patents (OECD, 2002). 
 
Patent takes place at the centre of the competitive strategy for the companies which are 
commercializing wide variety of technologies and innovation. Ideas or innovations of 
biotechnology companies might often be their only assets. Intellectual property rights are 
often the company's biggest asset. Intellectual property rights have also higher value than the 
company‟s physical assets in general (Krohn, 2010). Thus, patent is a key factor in order to 
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obtain funding and commercial success for further development for biotechnology 
companies (Philpott and Jolly, 2004).  
1.1  Project 
This project covers a 60-credit thesis work of Hedmark University College Master program 
in Commercial and Applied Biotechnology – Commercialization of Biotechnology, 2011. 
The research has been conducted upon assignment from BioKapital AS at the Hamar Biohus. 
BioKapital AS has needed to optimize its patent portfolio and to find out what procedures 
should have been enforced in order to maximize commercial value of their patent portfolio. 
This dissertation covers a new approach to estimation of monetary value of core business 
patent and patent applications for biotechnology companies, especially for BioKapital AS, in 
different aspects. In this manner, significance of patent value and patent value determinants 
are in question.  
1.2 The Company: BioKapital AS 
BioKapital AS is the holding company of BoviBank AS, SpermVital AS, Cryogenetics AS, 
GenderGuide AS and BioBank AS. BioKapital has whole shares of Cryogenetics and 
SpermVital. As half of BoviBank‟s share belongs to BioKapital; 33.3 percentages of 
BioBank‟s and GenderGuide‟s shares are owned by BioKapital as well. Figure 1 shows 
share distribution of BioKapital AS. 
Figure 1. Illustration of the current ownership structure of BioKapital AS. 
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Main goal of BioKapital is to increase commercial value of a selected portfolio of the 
daughter companies to the greatest degree. They are planning to achieve this goal through 
active ownership, capital providing for successful growth, senior research and development 
expertise, commercialization, IP management and relevant industrial experience. The 
daughter companies are focusing on the global agriculture and aquaculture industries. Their 
main fields of expertise are; artificial insemination (AI) and fertilization, gender selection, 
gene interaction, storing biological material and data, and the portfolio that will be 
developed on these basis. The aim of the portfolio companies is to enhance effectiveness in 
food value chains by implementing novel biotechnological methods (2011a).  
BioKapital has also international activities such as SpermVital AS - Geno Italy srl 
collaboration. In the end of 2009, Geno Italy srl started selling SpermVital‟s semen to Italian 
dairy farmers. SpermVital semen is a revolutionary new technology and is the final product 
of nearly a decade of research. SpermVital has had aimed to immobilize or "arrest" the 
sperm cell to save energy of sperm cells in order to ensure the sperm cells to survive for a 
longer period of time after insemination. For dairy farmer this application makes timing of 
insemination less critical and increases the chances of cow getting pregnant. The SpermVital 
process successfully combines immobilization with conventional cryopreservation 
techniques, so that SpermVital semen is stored, distributed and 
inseminated like conventional semen (AS, 2011).  
Patent application of SpermVital semen was published on 10 January 2008 and patenting 
SpermVital semen obviously encouraged BioKapital to do international business 
strengthening the patent portfolio. Estimating value of patent helps BioKapital and 
BioKapital‟s portfolio companies to remove uncertainties through patent filing process and 
to better managing the portfolio. 
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2. Introduction 
2.1 Patenting Process 
To be able to estimate economic value of a patent, it is required to understand how patenting 
process is conducted. Overview of the typical process of patenting an invention is showed in 
Figure 2. 
 
Figure 2. The figure summarizes a typical patenting process. In general, it starts 
with disclosure of invention to a patent attorney and then patentability search is 
carried out by industry professionals or inventor. According to the search results, 
patent application is submitted to the patent office (e.g. EPO, USPTO) or patenting 
process is terminated. After initial examination of the application at patent office, 
application is published. After patent is publicized, invention is granted with 
patent; as long as the substantive examination is completed without any crucial 
objection. During the examination steps, necessary arguments and amendments 
may be carried out between patent office and inventor/attorney.  Maintenance fees 
are paid at particular terms during patent lifetime. There is a nine months 
opposition period after patent is granted for competitors. Opposition is the last 
chance to attack a European patent as a single entity in a single forum. Later, the 
patent can only be opposed in national courts (Office., 2007). 
 
2.1.1 Disclosure of Invention 
In general, patenting process starts with inventor‟s disclosure of the prior art to a patent 
attorney (EPO recommends inventors to recruit a patent attorney to avoid costly mistakes 
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through application process) or a company which can be interested in the invention. In this 
step, if inventors think that their invention can be defended, then they should prepare a 
disclosure document of the invention in written form (non-disclosure agreement to prevent 
possible infringement of invention). Briefly, the disclosure document (a non-disclosure 
agreement) contains statement of invention (statement of prior art), drawings, name of 
inventor (s) and list of important dates related to the invention (2011b). In other words, 
disclosure document should answer some basic questions such as what is the invention, how 
can it be used, how does it work and etc. There can be some drawings in the disclosure or 
descriptions if it is a new method or developed version of a previous invention. Moreover, it 
is important to have a detailed documentation of the work such as laboratory reports in 
addition to references to the drawings before disclosure of invention. The disclosure should 
be dated and signed by inventors and two more individuals as witnesses other than inventor 
or co-inventors, witnesses should be able to understand the basics of the technology (Colitz, 
1995). 
 
Apparently, inventor‟s disclosure is one of the solid steps for monitoring how the value 
increases since the patent attorney may contribute to estimating value of the patent by 
opining on invention (Macdonald and Lefang) . 
 
2.1.2 Patentability Search 
To determine patentability of a technology, inventions are evaluated in light of existing prior 
art (Atal and Bar, 2010). Patentability search is useful before preparing and filing a patent 
application. The search results help determine whether to pursue protection and may indicate 
what issues could arise during examination of the application. After disclosing the invention 
to a patent attorney, comprehensive search is done by industry professionals (Hunt et al., 
2007). Patentability search is mainly based on claims of the invention for novelty. In the end 
of patentability search results are reported to gives an initial opinion on the patentability of 
the invention and to help better reconstruction of the claims. Hereby it is aimed to achieve 
the broadest protection without stepping on the known prior art (Foglia, 2007). According to 
the patentability search results, patent application is prepared and submitted to the patent 
office. Therefore, patentability search of invention has also a crucial effect on patent value. 
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2.1.3 Application and Publication 
Inventors usually apply to the United States Patent Office (USPTO) or European Patent 
Office (EPO) to patent their invention. When the patent application is received, an initial 
examination is carried out by the patent office. In case of any mistake in the application, 
applicant makes correction and resubmits the document. Patent application is filed with a 
filing date. For EPO, eighteen months after filing patent application, inventor‟s patent 
application is published (Aoki and Spiegel, 2009).  
 
Inventor‟s application can be seen by other people around the world in patent databases. This 
publication acts as prior art against other inventors or companies for similar invention 
(Office., 2007). The period after the filing process is called “patent pending”. This is 
warning for excluding the competitors and attracting potential investors. For example, most 
of the pharmaceutical companies try to have license of novel medicines before patent of the 
medicine is granted. Because pharmaceutical companies need a new product every three to 
five years in order to maintain growth. This need is often met by licensing a product from a 
competitor (Fitzgerald, 1992). As a part of the thesis, it is assumed that patent value would 
increase with publication process in case of acquisition offers from the competitors. 
 
2.1.4 Substantive Examination: Patent Pending 
After filing of the patent application at a relevant patent office, when the examiners check 
the application to determine its patentability, they must see that the invention is useful, non-
obvious and novel (Colitz, 1995). Duration of the examination is a critical period not only 
for owner of patent/invention but also the market, because a pending patent produces 
uncertainty for all the parties in relevant market. Patent pendency may distort rival firms' 
investment decisions since it is a signal to rival firms. In other words, competitors get aware 
space of a specific technology may already be owned. Definitely, the strength of this signal 
depends on the probability of being granted (Palangkaraya et al., 2008). In this manner, 
„‟patent pending‟‟ has a relative effect on patent valuation. 
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2.1.5 Decision 
Apparently, the most important value determinant stage of patenting process is decision on 
granting patent. If the patent application fulfils the requirements of patent office and all 
charges have been paid, patent examiners decide to grant patent under examination. Granting 
process takes on average 4.2 years from date of filing the application for a European patent 
(Harhoff and Reitzig, 2004). After a patent is published in relevant patent bulletin, 
maintenance fees are paid at particular intervals to keep patent in force (Colitz, 1995). Last 
process of the granting stage is opposition period. This period is nine months after 
publication of the mention showing that a European patent has been granted. Anyone can 
give the EPO notice of opposition to the patent, except for the proprietor (European patent 
office, 2009). If the opposition period ends without any opposition, invention completely 
becomes an asset of the inventor. Thus, invention can be driven into market safely with less 
risk and more value. 
2.2 What Value of a Patent Means 
The value of a patent is the future commercial utility of patented invention. A patent value is 
derived taking into account all necessary economic and technical aspects and risks. Patent 
value is that how much money can be earned on patented invention out of the cost (Office, 
2010). In that case, there are three concepts which should be defined to better understand 
notion of patent value; value (individual utility), price (exchange value) and cost. These 
three notions can be explained with an example; For instance, cost for a bottle of water can 
be 0, 2€ and the price for a bottle of water probably vary between 0, 3€ and 2€. Whilst a 
customer may buy a bottle of water paying 0, 3€ from super market, the customer may pay 
2€ for the same bottle of water in a gourmet restaurant. As to notion of value (individual 
utility), a bottle of water may even be priceless, if the customer in the middle of a desert. 
Therefore, value of something depends very much on the situation where the asset is used 
and who is using the asset. For example, value of a bottle of water is absolutely different for 
a man and for a camel (Schaaf, 2009). In general, those three main concepts are taken into 
account for patent valuation.  
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2.3 Why Estimating Value of an Patent  
For some decades, patent and statistics about patent evaluation have been under close 
examination by economists and policy-makers (Harhoff et al., 2003).  In addition, 
technology transfer institutes, banks and venture capitalists have been interested in value of a 
patent beside the patent owners themselves (Office, 2011). In this chapter, reasons for 
estimating value of a patent are explained. 
 
Patent is an intellectual property as pointed out in the previous sections. In the last 15 years 
there has been a remarkable increase in the number of companies that  have become leaders 
through the effective creation, extraction and leveraging of their IP through efficient IP 
management. Yet, the role of IP in business has not sufficiently understood in most cases. 
Small and medium enterprises, the building blocks of many developed economies have 
failed to quickly realise the potential of IP management in increasing their competitiveness 
(EPO, 2009). Thus, many governments have taken a stand in the promotion of such IP 
management business practises.  
 
The primary reason for such promotion is to maximise its value and therefore the value of 
the owner organisation through optimum management decisions. There are various situations 
where valuation is needed, and some examples are given below. 
Company valuation (transactions, joint ventures, mergers and acquisitions, 
bankruptcy) 
IP is an essential component of company value. A precise IP valuation is required for 
acquiring or selling a company, setting up joint ventures, and executing mergers and 
acquisitions. In such transactions, each party will need to know the value of purchased and 
sold IP assets as part of the company. In case of company‟s bankruptcy or reorganisation, 
assessment of the company‟s value is required, and this must include the value of IP assets 
and the assessment of the impact of proposed reorganisation plans (EPO, 2009). 
Sale and license transactions 
Before a company buys or sells IP, it must be aware of its value. Likewise, when negotiating 
a license contract, both parties must be clear about the values involved. Often, a due 
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diligence report is required in outlining the details of the purchased, sold or licensed IP 
(EPO, 2009). 
Raising finance  
To finance their development plans, many knowledge intensive companies can only offer 
their own IP as collateral. More recently, there has been increasing debate about the 
collateralisation of IP in both cash flow based financing and asset based financing. Due to 
insufficient knowledge about IP and its valuation, banks are as still reluctant to accept such 
assets. In the future, this type of collateralisation will be more accepted in the industry and IP 
valuation will become a key process. Financing through venture capital is also important for 
many (especially knowledge based) companies. As well as, for legal entities, knowing the 
value of their IP is important for possible tax deductions and tax compliance (EPO, 2009). 
External reporting and accounting 
In general, accounting standards are not useful when IP is represented in company accounts 
and often it causes to undervalue and mismanage the IP. Accurate IP value estimation is 
required for many aspects of reporting and accounting such as the reporting of fair value 
estimates in annual reports of the company. In addition, precise estimation on IP value is 
also needed in the event of intellectual property rights infringement or breaking of a legal 
agreement on an IP (EPO, 2009). 
Internal management 
The successful exploitation of IP (for example in the ways outlined above) can lead to a 
company‟s success or failure. IP exploitation and creation of business strategies require 
effective management within the company. Research, development, legal, industrial 
protection application and commercialisation decisions involve high but measurable levels of 
risk. IP valuation facilitates cost effective decision-making and helps to understand and deal 
with the risks involved (EPO, 2009). 
 
To evaluate a patent, there are several reasons depending on the technology in question, 
these are optimization of patent portfolio expenditures, remuneration of inventors, 
positioning of patent strategy to overall business strategy, financing, licensing, mergers and 
takeovers, accounting (IAS 38), enforced evaluation in case of bankruptcy and damages 
(Office, 2011). 
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Licensing is the major reason for evaluation of a patent. Patents are constituent of 
intellectual capital of innovative companies. Valuation of a patent can be helpful in 
discovering potential licensing income sources, and arranging the licensing fees (van Triest 
and Vis, 2007). Therefore, to be able to perform a solid portfolio management of patents and 
patent applications for innovative companies, it is crucially important to obtain an estimate 
on economic value of patent (Sullivan, 1994) and understand what are the most remarkable 
factors on determining value of patent. Since biotechnology is a highly innovative field 
(Hunt et al., 2007), estimating economic value of patent also has a special significance for 
biotechnology companies. 
 
2.4 The Literature on Patent Value 
In this section, related definitions and explanations to patent value, determinants of patent 
value and patenting process are given. 
Since the first studies in 1960s, researchers have studied a variety of patent value 
determinants such as patent breadth, novelty, disclosure, and inventive activity; and most of 
the literature relating to patent value focuses particularly on theoretically modelling of the 
patent system (Holger Ernst 2010).  
 
2.4.1 Patenting Process and Value Determinants of Patent  
In the economic literature, it is assumed that value of patent is mainly determined by number 
of times the patent is cited, length of its renewal and number of countries where the patent is 
granted. In most of studies relating to estimating value of patent, this information is used in 
different functional forms (Guellec and van Pottelsberghe, 2000). However, there are also 
several other parameters which may better contribute to determining value of patent at 
different stages of patenting process. This research is dealt with these most remarkable value 
determinants and their relative effects on estimating value of patent at each stage of 
patenting process. 
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Value of a patent can be calculated empirically by using several different criteria at different 
stages of patenting process. Value of a patent increases through patenting process -from 
invention to granted patent. The darker the zone gets, the higher the value of inventions have 
(Guellec and van Pottelsberghe, 2000). Figure 3 demonstrates a value scale in the universe of 
inventions.  
 
Figure 3. The figure illustrates a patent value universe. In zone 1, a new 
technology emerges; invention has the lowest value. At the application stage, 
invention has more value as compared to space 1. From zone 3 to zone 4, invention 
reaches the highest value by getting granted (patented) and increasing market 
demand. After patent expires in zone5 ,invention’s value decreases to the level of 
zone 2  (Guellec and van Pottelsberghe, 2000). 
 
Invention value can be guaranteed to some degree with patent. However, it is also well 
known that value of an innovation can change after patent granted, often dramatically for 
many different reasons. One of these reasons is technological substitutions. New technology 
may appear to supplant the old one, making the old one partially or totally useless and hence 
less valuable. In a contrary manner, complementary technology may be developed in a way 
to enable better commercialization of an old innovation which previously could not be 
implemented very well. 
 
The other reasons are commercial; the market for the related invention may simply disappear 
because of a change in „‟consumer taste‟‟. Or the complementary assets used to 
commercialize the innovation could increase the value of the innovation in the process. 
Furthermore, innovators may have different ability to commercialize their innovations, and 
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the value that the innovator can obtain from commercialization depends not only on the 
appropriability regime
1
 but also on the commercialization strategy the innovator chooses 
(Sherry and Teece, 2004). 
2.5 Main Value Determinants of Patent  
In the following section, it is intended to define and understand most remarkable patent 
value determinants directly regarding invention itself and how the determinants affect the 
patent value at each step of patenting process. 
2.5.1 Lifetime 
Mainly, all models of patent value assume that the value of a patent increases monotonically 
during its lifetime with exponentially decreasing marginal returns. The literature strongly 
suggests that returns by patents per period are not constant, but that they rather increase until 
the global maximum of the technology cycle to decrease again (Reitzig, 2003). Lifetime of 
the patent is prolonged with renewals according to technology of the invention and 
continuity of its utility. However, for specific inventions such as effective or common 
medicines like aspirin, the main factor on patent value is total financial returns per period as 
well as the technology. Additionally, the litigations and oppositions against a patent by 
competitors can also push the patentee to renew the patent. And so, we can see that there are 
also many sub parameters affecting the lifetime of patent. 
 
Lifetime of patent was first introduced as a patent value determinant in a study by Gallini 
(Reitzig, 2003). Remaining life time of a patent is a significant indicator of the value as 
shown in Figure 4 (Sherry and Teece, 2004). 
 
                                               
1 The appropriability regime means those factors that influence a firm‟s ability to capture profits, which are: the nature of 
the technology; and the strength of legal barriers against imitation. TIMOTHY, O. H. 2006. Guarding Profits From 
Innovation: Successful IP Strategies. In: DAY, J. (ed.). 
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Figure 4. The figure indicates how patent value changes as the milestones are 
reached (throughout invention’s/patent’s lifecycle) (Sherry and Teece, 2004). 
 
2.5.2 Novelty and Inventive activity 
In intellectual property literature, novelty is defined as the technological distance between 
prior art and the patented invention. Inventive activity is described as the technological 
distance between existing technology and patented invention regarding obviousness. The 
degree of novelty and inventive activity are essential to fulfil patenting requirements, which 
determines value of the patent for the patent owner.  
 
In several empirical surveys, backward citations
2
  appear as significant indicators of patent 
value (Reitzig, 2003). Another study (Ma and Lee, 2008) emphasizes three different factors 
which have been frequently used to examine the various aspects of inventive activities: (1) 
R&D expenditure, (2) number of scientists, engineers, technicians, and (3) patent statistics. 
In  many empirical surveys in the scope of assessment of patent, researchers have found that 
                                               
2 If Patent A (1993) is cited by Patent B (2003) then: Patent A is a backward citation of Patent B;  Patent B is a 
forward citation of Patent A. 1.15.0, M. 2009. Citations [Online]. Available: 
http://www.intellogist.com/wiki/Citations [Accessed]. 
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novelty and inventive activity have significant characteristics to estimate value of patent 
(Reitzig, 2003). 
 
2.5.3 Difficulty to invent around (infrangibility) 
Inventing around is to work on previously patented invention and take patent of this new 
modification of the previous invention. In other words, it is a legal infringement of previous 
patent. Therefore, inventing around is a risk for previous patent owner but opportunity for 
competitors. Because of inventing around risk, inventor companies prepare their claims of 
patent application very carefully and revise their application many times via guidance of 
patent attorneys to block the others as much as possible. Increasing the difficulty of 
inventing around also increases the competitors‟ costs and time for imitation for inventing 
around the patent. In this way, competitors‟ willingness to pay for a license increases too or 
it keeps the competitors away from the market, thereby patent value increases (Granstrand, 
1999). Inventing around is a value determinant for patent practitioners. However, how 
strongly value of patent is affected by inventing around parameter is not exactly known 
(Reitzig, 2003).  
 
2.5.4 Breadth of a patent 
Claims of a patent determine its breadth. Theoretically, higher numbers of the claims provide 
larger size for breadth of patent. Not only number of claims but also scope of the claims 
determines broadness of the patent. Value of a patent increases with scope (number of 
different technologies of the patents) for American Biotechnology firms. It is assumed that 
breadth of a patent provides positive return to the inventor‟s (patentee) profit positively 
(Reitzig, 2003). Inventors try to keep the claims of patent application broad as much as 
possible to maximize innovation rents (Yiannaka and Fulton, 2006). A higher number of 
claims or a larger scope of invention can cause the oppositions (litigation) against patent by 
competitors (Harhoff et al., 2003). Number of oppositions against a patent is a sub value 
determinant of the breadth too. Breadth of a patent should be involved in patent valuation, in 
each step of patenting process.  
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2.5.5 Portfolio Position  
Patent portfolio is a list of patents belonging to an individual or a company. Managing the 
patent portfolio and comparing it to those of other companies are necessary for technology 
producing companies in order to justify economic expenses and economic value of their 
patents and to maintain their competitiveness in the market. Patent portfolio management 
also cover identification of opportunities and risk factors (e.g. growing markets and emerging 
of competitive substitute technologies) (Office, 2011). 
 
It is emphasized that a company‟s patent portfolio is increasingly regarded as of major 
interest for strategic business development decisions in Littman-Hilmer‟s analysis on patent 
portfolios (Littmann-Hilmer and Kuckartz, 2009). In Reitzig‟s study, it is also mentioned 
that value of a single patent can depend on overall patent portfolio of the patent owner 
(Reitzig, 2003). Size of the portfolio and function of a single patent in this portfolio affect 
value of patent. Portfolio position of a patent must be taken in to consideration for estimating 
patent value. 
 
2.5.6 Market Size (market value) and Status of Commercialization & 
Production 
Market size of invention, namely patented product, is an inevitable value determinant of 
patent. It is better to figure on this determinant as observing the changes on patent value at 
all phases of patenting process. Therefore, the better investigation and knowledge about the 
relevant market of invention contribute to companies for estimating patent value. IPscore® 
also requires inputs about marketing conditions of the product/invention. By achieving the 
proper amount of financials, innovation can get passed into production step. 
 
Production of the invention is dependent status of commercialization (Zimmerer et al., 
2008). Commercialization is the process that converts ideas, research, or prototypes into 
viable products that retain the desired functionality, while designing them to be 
readily available at low cost and launching quickly with high quality design. 
Commercialization may be a necessary step for commercial success for innovations coming 
from enterprise or company research efforts (Anderson, 2010). 
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2.5.7 Geographical Coverage (patent family) 
In a study by Harhoff et al., (2003), geographical coverage is used as one of patent value 
indicators. A patent family is a set of either patent applications or publications taken in 
multiple countries to protect a single invention by a common inventor(s) and then patented in 
more than one country. A first application is made in one country with the priority and then 
extended to other offices (Office, 2007). In the pharmaceutical and biotechnology areas, one 
should file in countries in which the major pharmaceutical companies have established 
research-and-development facilities. These countries would include the United States, the 
United Kingdom, Japan, Switzerland, France and Germany (Fordis, 2006). Hereby, value of 
a patent is supposed to change in correlation with geographical coverage of the patent. 
 
2.5.8 Difficulty of Proving Infringement 
Difficulty of proving infringement was chosen as value determinant first time by Markus 
Reitzig in 2003. In materials and methods section, it is asked „‟ whether it is easy to 
differentiate infringing copy products from the original‘’. 
 
2.6 How do companies valuate their patents  
In fact, there are nearly as many potential methodologies to estimate the value of patent as 
the number of existing investigations (Sapsalis et al., 2006). And most of those solutions are 
highly variable depending on the technological field and market conditions. On the other 
hand, there are a number of common models which are accepted by financial and accounting 
professionals in general. In brief, these are the cost-based model, the market-based model 
and the income-based model (Review, 2006).  
 
In ip4inno student handbook (EPO, 2009) methods for valuation of intellectual property is 
explained. According to this source, depending on the reason for the patent valuation, a 
specific valuation approach or a combination of approaches is chosen. For example, patent 
valuation for the purpose of internal management requires an internal value; for sale or 
licensing, and a market value. These two valuations may not be equal. A number of 
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approaches have been proposed and each has their own set of unique strengths and 
weaknesses. It is important to choose the appropriate method or toolbox of methods for each 
individual case, to obtain an optimal result. In practices each valuation toolbox is likely to 
include more than one of the methods discussed in further sections. The most important 
parameters to consider during valuation of the patent and selecting the appropriate toolbox 
are the following: 
 
What is the purpose of the valuation? 
The type of value (internal, market) and the type of required value result (qualitative, 
quantitative) is determined by the purpose of the valuation. Different value estimation 
methods are applied according to the target group. The target groups can be potential 
investors or internal management (EPO, 2009). 
 
Date of the valuation 
Appropriate value estimation method is chosen according to time of patent valuation. For 
instance, expected licence income of a patent can be calculated for next 5 or 10 years 
depending on remaining lifetime of the patent or remaining lifetime of licensing agreement. 
Assume that subject patent has 10 years remaining lifetime from date of evaluation then 
evaluation for license income is carried out for 10 years, but not for entire lifetime of subject 
patent (EPO, 2009). 
 
Methods, which are used for business purposes, can be divided into two groups. These are 
qualitative and quantitative valuation methods in general. The qualitative methods provide 
a value guide through the rating and scoring of patent on the basis of factors which can affect 
the value. The quantitative valuation methods are used to calculate the monetary value of 
patent and include cost, market, income and option pricing approaches. Summary of 
commonly used methods is given below (EPO, 2009).  
 
2.6.1 Quantitative Evaluation Methods 
Cost based methods 
Cost based models measure the value of IP quantitatively through the calculation of the 
incurred costs if the company is to develop a similar asset either in-house or externally. The 
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costs to produce the IP are taken to be its value. Cost based methods include the historic 
cost, replication cost and replacement cost models. The historic cost model measures the 
costs incurred through the development of the IP, when it was developed. The replication 
cost model measures the amount of investment needed to develop similar IP, at the present 
time, in exactly the same way and achieving the same IP as currently exists. The whole cost 
of research and development must be included in this calculation, including the costs of 
unsuccessful prototypes as well. The replacement cost approach measures how much money 
would be needed to develop the current IP. Yet, as the term “replacement” implies, the costs 
of failed and unsuccessful research are not included. It is easier to think of this in measuring 
the cost of purchasing the already developed IP from an external source (EPO, 2009). 
 
Approaches based on the measurement of cost are generally used in accounting, 
bookkeeping and in accordance with accounting rules. The cost based methods cannot be 
used to solely estimate monetary value of a patent. They are only relevant in historical cost 
based accounting systems or where taxation methods are relevant to use. Main advantage of 
this method is that patent becomes visible in the company‟s books and IP awareness is 
increased. The method is also a useful indicator of IP value in case of IP assets whose future 
benefit is not evident (EPO, 2009).  
 
There are many pitfalls related to using the measurement of cost to determine the value of 
IP. The main disadvantage is that there is no direct correlation between cost of development 
and the future revenue potential of assets. Actually, most costly IP may not necessarily be 
the most valuable. The same applies to old IP which has been written down in value. This IP 
could still be the most valuable for the company, even though the historical cost approach 
does not show this. The measure of historic costs is unreliable with rapid technological 
advancement. It is not always possible to provide accurate information on the resources 
spent on development and there will always be a practical challenge to determine which 
costs to include or exclude. Most importantly, cost based methods make no allowance for the 
future benefits which might accrue from the IP (EPO, 2009). 
Market based methods 
Market based methods value IP through comparison with prices achieved in recent 
comparable or similar IP transactions between independent parties. Observing the prices of 
comparable assets traded between parties in an active market gives a value to the subject IP. 
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The idea behind these approaches is that the market decides the accurate price and therefore 
the value of the IP. Market based methods include IP auctions, comparable market value and 
comparable royalty rate methods. In an ideal IP auction, there are many potential buyers with 
ideal information about all aspects of the IP. The value of the IP is determined by the price 
reached through bidding. Comparable market value method, the value of the IP is given by 
comparison with similar comparable independent IPs or similar transactions (EPO, 2009).  
 
Market based valuation methods may also be based on the comparison of royalty rates used 
when licensing similar IPs. Many sectors often use industry averages as a basis for setting 
royalty rates in license agreements or in establishing damages in litigation. The value of the 
IP is given through the comparison of the subject IP with the royalty rates in similar license 
agreements (EPO, 2009). 
 
Market based methods are useful when a market value is required for any given subject IP. 
These methods require an active market, a comparable exchange of IP between two 
independent parties and sufficient access to transaction price information. However, there 
are limited formal markets for IP and the relevant pricing information is not usually public. 
As a result, the use of the comparable market value approach to valuing IP is rare. The use of 
comparable royalty rates are more widespread, especially as databases of industry royalty 
rates and comparable transaction information have been collated by larger IP right-holders 
and independent companies offering valuation services. In the future, when IP markets 
become active and public, the use of market based approaches can become more established 
(EPO, 2009). 
 
Observing the market is a relatively straightforward valuation method. It is useful to check 
the validity of other approaches. As well as the issues raised about the lack of IP markets and 
information, there are many other disadvantages to these approaches. Firstly, the uniqueness 
of IP makes direct comparison difficult. There is a risk of comparing the subject IP with 
other IP which has been traded but has still not been utilised to the possible full extent. In 
these cases the IP can be undervalued. When royalty rates are compared, there are also some 
potential distorting problems. Royalty rates set using returns to R&D costs, return on sales 
figures or industry averages run the risk of valuing costs or other factors rather than value 
(EPO, 2009). 
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Income based methods 
The most fundamental definition of the value is dependent on the capability of an asset to 
generate future income, and this is especially valid for IP. Income based methods attempt to 
estimate the potential future benefits of the IP in an effort to determine its value. There are 
many income based valuation methods; each of these methods differs from each other 
according to the reason for the valuation and the type of industry. Some of the income based 
methods comprise the discounted cash flow (DCF), risk adjusted net present value (rNPV), 
relief from royalty methods and the technology factor method (EPO, 2009).  
 
Discounted Cash Flow (DCF) 
The Discounted Cash Flow (DCF) is the most basic and common model of the income based 
valuation approaches. This approach attempts to determine the value of the IP by computing 
the present value of future cash flows from the IP. The methods under this category are all 
centred around evaluating these future cash flows and then discounting them back at a 
discount rate to achieve a present value (Cooper et al., 2005). The two key factors which 
must be accounted for in a DCF calculation are the time value of money and riskiness of the 
forecasted cash flows. These are dealt through the use of a specific discount rate chosen 
specifically for the subject IP, which accounts for both factors at once. Alternatively, the 
forecasted cash flows can be adjusted to account for their riskiness and changing riskiness 
over time. These are then discounted at a risk free rate, which accounts for the time value of 
money (EPO, 2009). 
 
Risk adjusted net present value (rNPV) 
Risk adjusted net present value (rNPV), approach is an extension of the DCF method mainly 
used in the pharmaceutical and biotechnology industries. It was developed to deal with 
technical risk during the development of IP assets such as in medicines. To explain risk, the 
method adjusts the cash flows of each stage of development by fixed probability rates based 
on established industry indicators. For example, the statistical probability of successfully 
completion of the first stage of clinical trials may be 20%, second stage is 30% and so on. 
The cash flows are risk adjusted using these probability rates and discounted as with the 
DCF method (EPO, 2009). 
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The relief from royalty  
The relief from royalty method measures the royalty that the company would have to pay for 
licensing the valued IP, to a third-party. The royalty represents the rental charge, which 
would be paid to the licensor if this hypothetical arrangement were in place. The method 
assumes that the value of the IP is defined as the rental charge that other companies would 
pay to use it. Estimating this royalty rate is only a first step. A reliable sales forecast is also 
required in order to estimate the income flowing directly from the IP. As with other income 
approaches, the royalty rates are discounted through an appropriated discount rate (EPO, 
2009). 
 
The technology factor method 
The technology factor method firstly estimates a risk free net present value for the IP 
(similarly to the DCF method) and then multiplies this with a risk-factor, or “technology 
factor”. The technology factor value is derived from attributes reflecting the commercial 
strengths and weaknesses of the IP. Aim of technology factor method is to understand 
technical (in case of technology), legal, market and economic risks related to the valued IP 
(EPO, 2009). 
 
Income based approaches for IP valuation is only precise, if the following variables are 
available or can be accurately estimated: An income stream either from product sales or 
license of the IP, an estimate of the duration of the IP‟s useful life, an understanding of IP 
specific risk factors for incorporation into the valuation and a valid discount rate (EPO, 
2009).  
 
The advantage of income based methods is that it is relatively simple to assess the value on 
the basis of the setup conditions. With the probable availability of many of the required 
inputs from the firm‟s financial statements and market information, it may be possible to 
identify and or forecast particular cash flows. The methods are conceptually strong but can 
be difficult to implement in high-uncertainty environments. This task always includes some 
uncertainty and subjective assumptions (EPO, 2009).  
 
A significant disadvantage of these methods is that both uncertain and distant cash flows and 
the discount rate have to be estimated. For example, there is rarely an experience base when 
estimating the market potential and therefore cash flow of early stage IP developments. In 
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addition, all risks are lumped together and are assumed to be appropriately adjusted in the 
discount rate and the probabilities of success, rather than being dealt with individually (such 
as legal risk, technological risk etc.) (EPO, 2009). 
 
A significant disadvantage of the relief from royalty method is that a royalty rate can always 
be assumed, while it may never materialise in reality. However, in specific circumstances 
this method is useful, especially if there are suitable comparable transactions involving third 
parties or industry standard royalty rates (EPO, 2009). 
Option pricing based methods: Expected Commercial Value 
The theory behind option pricing was primarily developed for use in pricing financial 
options, but can also be applied to a number of other situations other than directly financial 
assets. The valuation of IP in development or already commercialised is one such framework 
(EPO, 2009). Option based methods essentially are in the income based methods category as 
they similarly use expected future cash flows to measure value. Calculation of expected 
commercial value of a project is explained in figure 5.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The basic definition of an option is a right but not an obligation, at or before some specified 
time, to purchase or sell an underlying asset whose price is subject to some form of random 
Figure 5. The figure shows calculation of the expected commercial value 
(ECV) from a project (Cooper et al., 2005). 
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variation (Pitkethly, 2002). Options are priced using the Black-Scholes option-pricing 
model, which is a mathematical model for the valuation of options. 
  
Real option valuation methods treat the development and commercialisation of IP as a series 
of options. As the IP is developed and commercialised, many decisions about investment 
timing, when to patent, abandonment, direction of research etc. must be made. The 
information to make these decisions is often not available at the time of valuation, but 
becomes available later. The real options method, using the Black-Scholes model, takes into 
account the flexibility of these future decisions (EPO, 2009). 
 
The primary advantage of the real options method is its ability to incorporate the value 
associated with the uncertainty and to account for the flexibility inherent in the development 
of IP. The value associated with the uncertainty of cash flows and the ability to manage the 
development of the IP is accounted. Like the DCF method it values the stream of cash flows 
but it also accounts for acquired knowledge. As a result, it provides a more complete 
evaluation than the DCF as it captures more than simply cash flows and static costs. The 
main disadvantage of the real options method is the complexity of the model. It is difficult to 
understand and the evaluation can be costly to perform. Some experts doubt the accuracy of 
options based models for use with real investments such as IP. The main arguments are that 
option based models overvalue IP through the inclusion of non-viable development and 
commercialisation decisions (EPO, 2009). 
 
The real options method is particularly applicable when there is a high degree of uncertainty, 
some managerial flexibility, and not all the information is known at a particular time. It is 
increasingly used in the biotechnology and pharmaceutical industries and early stage of IP 
developments (EPO, 2009). 
 
2.6.2 Qualitative evaluation methods 
Qualitative valuation methods provide a value guide for the subject IP through the rating and 
scoring of different factors related to the IP. These factors or “value indicators” can 
influence the value of the IP both positively and negatively. In the same way, factors such as 
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location, numbers of rooms, nearby schools affect value of a house. A combination of these 
IP related factors acts as a proxy for the value of the IP (EPO, 2009). 
 
In the case of patents, there is evidence to suggest that there is a strong correlation between 
patent value and standardised indicators which are observable in patent information 
documents. For example, the number of references to prior patents generated during the 
search and examination process, and the number of citations a patent has received indicate 
its importance scientifically and therefore its relative value. The observable result is a 
network of links called a patent citations network which is a useful qualitative evaluation 
tool. Likewise the number and quality of claims, the patent family size and the outcome of 
oppositions to the patent application can also be an indication of value. An example of this 
type of qualitative valuation method is the IPscore (In section 2.7, IPscore is described and 
discussed thoroughly). 
 
The main advantage of patent information related and non-patent value indicators is their 
relative simplicity. Once the relevant information has been researched and is available in a 
useable form, it is relatively easy to classify and evaluate the IP without need for complex 
methods. Another advantage is that the data for the evaluation is often publicly available. 
With sufficient expertise, it is possible to value IP belonging to other parties. As a result, 
these qualitative methods facilitate the comparison and ranking of IP within a company‟s 
own portfolio or against competitors‟ IP. Valuing IP using patent information related value 
indicators has many drawbacks. For example simply counting citations avoids taking a stand 
on questions such as how and why citations arise and what type of information they convey. 
Focusing on simple counts deliberately ignores any added information within the network of 
citations. Using value indicators as a proxy for value is only as useful as the level of 
expertise of those who are conducting the valuation. One must also decide which indicators 
are relevant to the value of a particular IP. The quality and realism of the qualitative 
evaluation in IPscore, for example, are greatly dependent on the quality of information used. 
 
Qualitative evaluation methods are most often used for the purpose of internal IP 
management. They are most useful for comparing, categorising and ranking IP within a 
portfolio or comparing with competitors‟ IP. They are also useful for assessing the risks and 
opportunities of IP (EPO, 2009). 
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2.7 Estimation of Patent Value by IPscore® 2.2 
EPO currently brings in a software tool, IPscore® which combines the previously mentioned 
methods as in section 2. 6 of present thesis, for the innovative companies who need to 
understand and predict the value of their inventions (Nielsen E, 2004).  
 
IPscore® 2.2 is a tool for evaluation of patents and technological development projects. It 
provides both qualitative and quantitative evaluation in the form of a financial forecast 
showing the net present value of the evaluated technology. In addition, IPscore® 2.2 
produces output in the form of graphical overviews and a report to facilitate communication 
of the evaluation results.  
 
At first, The Danish Patent and Trademark Office developed IPscore® 2.0 in 2001, in 
collaboration with the Copenhagen Business School and a number of Danish companies. In 
2006, The European Patent Office purchased the tool from the Danish Patent and Trademark 
Office. In 2009, The European Patent Office developed IPscore® version 2.2 which is a 
multilingual (English, German, French) and slightly improved version. IPscore® 2.2 is made 
available to users free of charge in order to support the patent strategy of companies, mainly 
SMEs and to steer the volume of applications by eliminating potentially “worthless” 
applications (EPO, 2009).  
 
IPscore® 2.2 includes a mathematical model and do not promise accuracy for the results of 
the financial analysis of the evaluated patented technology. The patent‟s actual value may be 
significantly higher or lower than the value calculated by IPscore®, because the value is 
influenced by many commercial and economic factors which are not contained in the model, 
or other factors out of control (EPO, 2009).  
 
IPscore® is the most prominent evaluation tool for the comprehensive use. The IPscore 
assessment of a patent consists of five categories: legal status, technology, market 
conditions, financials and business strategy, each of which has 5-10 associated index 
questions (inputs).  Each question relates to a different value indicator. Each question is rated 
from 1 to 5 according to the patents strengths and weaknesses. Together, approximately 40 
value indicators form a whole picture of the patent and its relative risks and opportunities. In 
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other words, outputs of the computation are given in relation with patent profile, net present 
value of the invention, financial forecast, diagnoses, portfolio and supplementary reports. 
Results are also given in different forms such as radar diagrams, charts, written reports and 
graphics (Organisation, 2010).  
 
In appearance, IPscore® is a very appealing and useful tool for the patentees for estimating 
their patent value. However, when the user starts to put in necessary data, it is realized that 
user should have a comprehensive business plan to be able to evaluate the patent. This 
feature of IPscore® keeps itself away from practical use. Especially, inputs on the financial 
questions page of IPscore® prove the necessity for a business plan in order to approximate 
patent value. Figure 6 shows some required inputs of IPscore® for patent evaluation.  
 
 
Figure 6. The figure indicates one of the input pages from IPscore® 2.2. It is 
showed that the necessary data which are supposed to be entered in by the user. 
These data indicates that the user should have a business plan to be able to 
evaluate his/ her patent/patent application (Organisation, 2010). 
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2.8 Need for a Quick Method to Valuate Patent 
In previous sections, Intellectual Property Rights (IPR) and importance of patent especially 
for the biotechnology companies are emphasized. And following subjects are explained 
respectively; patenting process, notion of patent value, necessity of patent value estimation, 
patent value determinants, current IP evaluation methodologies used by the companies and 
estimation of patent value by IPscore. In summary, evaluation of the patent and patent 
application has vital role throughout the establishment of IPR strategy of companies. The 
companies are also required to have comprehensive business plan in order to use most of the 
current patent valuation methods.  
 
There is a need for quick method since the current methods are costly and highly and also 
divergent from each other in terms of type of technology and industry, market conditions. In 
addition, efficiencies of the present methods are also open to discussion. Herein, by offering 
a quick model it is performed to help biotechnology companies, especially start-up 
biotechnology companies for evaluating their inventions. This method can also be used for 
purpose of internal management of big biotechnology companies. 
 
In this thesis, it is attempted to develop a quick patent value estimation method, which is FF 
method, for core business patent (central patent) of biotechnology industry. There are three 
different types of patenting strategies for the companies establishing an IPR strategy.  The 
backbone patenting strategy of those three is central patent. Defensive patent is another 
strategy to belt around a competitor‟s patents in order to prevent expansion of competitor‟s 
IPR field. Defensive patent also fences for protection to restrict and protect the company‟s 
own area. Another strategy is to use a patent as bargaining chip, that is often used for cross-
licensing (Krohn, 2010).  
In this project, a survey was carried out to be able to develop a method for value estimation 
of patent. Underlying reason for developing central patent valuator method is that patents of 
the sample group of the survey were central patents. 
 
Table 1 shows which type of patent can be valuated with FF method in which way. FF 
method consists of two main components which are a questionnaire and a formula. The 
questionnaire was prepared based on determinants of patent value and interaction between 
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the determinants and patenting process. Whilst preparing the questionnaire and patent value 
determinants, which have been most often emphasized in the literature, were selected. Then, 
an equation deriving from the questionnaire was set up. Details of the questionnaire and 
equation are explained in materials and methods part. 
 
 Table 1.The table indicates place of my method on matrix of patent valuation methods. 
 
2.8.1 Aim of Project 
Specific aim of this project is to develop a model in order to estimate monetary value of 
biotechnological patents/patent applications quickly. Hereby, it was intended to help 
removing uncertainties during patenting process and develop better IPR strategies overall 
patent portfolio management of biotechnology companies. Under this main purpose of the 
study, sub-aims are listed like below;  
 
Sub-aim 1: To prepare a questionnaire converting most remarkable patent value 
determinants to the questions. 
Sub-aim 2: To carry out a survey amongst biotechnology companies for obtaining solid 
value (patent sales) by using the questionnaire (mentioned in sub-aim 1)  
Sub-aim 3: To develop a fair scoring method in order to evaluate results of the survey 
(mentioned in sub-aim 2); this would help to develop a proper mathematical formula 
depending on results of the survey, for further estimations on patent value.  
Sub-aim 4: To find out other possible mathematical formulations for further estimation of 
monetary patent value. Hereby, effect of the value determinants on the monetary value of 
patent is aimed to be observed individually. 
Sub-aim 5: To observe weight of the value determinants via a survey study using the 
questionnaire in the scope of the ongoing debate about which criteria is the most significant 
on patent valuation in the literature. 
Matrix of Patent Valuation Methods 
 Central patents Defensive patents Bargaining patents 
Comprehensive methods IPscore® IPscore® IPscore® 
Quick methods FF model   
 35 
3. Materials and Methods 
3.1 Progress of the Thesis Work 
During the thesis work period from September 2010 to May 2011, regular meetings were 
held with the supervisors, once a month. In the first meeting with participation of all the 
supervisors, it was aimed to determine the problem; BioKapital were looking for the possible 
strategies to be able to maximize economic value of their patents and patent applications. In 
the second meeting, it was decided to find a solution for obtaining an approximate monetary 
value of a patent since it is necessary to have an estimate on economic value of patent to 
justify research and development cost for accounting purposes. This would help to remove 
the uncertainties throughout the filing/patenting process. Hence, it was intended to achieve 
better patent portfolio management.  
 
After finding the problem, reading process was started and to be able to have a better 
background for analysis of the problem. Two months were spent for reading and one month 
for analysis of the problem. Following two months after the analysis step were used to 
develop a model for estimating patent value. Table 2 shows the timeline and progress of the 
thesis work. 
 
Table 2. The table demonstrates timeline of the thesis work. 
2010-2011 Thesis work study schedule 
Oct. Nov. Dec. Jan. Feb. Mar. Apr. May-Jun 
Reading 
 
Analysis of the 
problem 
Developing a solution for 
estimating patent value Obtaining the results   
  writing 
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3.2 Questionnaire 
In the beginning of February 2011, the questionnaire was prepared inferring from patent 
value determinants and IPscore®. The questionnaire was aimed at the patentees/inventors 
who have already sold or bought a patent, especially in biotechnology field.  
 
On the top of the questionnaire (Appendix 1), four boxes (identifier questions) were placed. 
Participants are supposed to fill the first three boxes optionally and the forth one 
compulsorily. In figure 7 these four boxes are demonstrated. 
        
The questionnaire consists of 13 main questions. There are also weighing questions in 
addition to each of the main questions.  
 
Each of the questions has multiple answers in a particular order. Choices of each question 
were aligned in a qualitatively ascending order by weight. For instance, whilst choice (A) 
(first choice in the order) would have the lowest weight, choice (E) (last choice in the order) 
would have the highest weight during evaluation (scoring).  
 
Each question of the questionnaire was prepared by being derived from patent value 
determinants. In this manner, different titles (representing scope of the question) were given 
to each of the questions in order to ensure the participants to better understand the questions. 
Figure 7. The figure shows the required information about the participant’s 
patent sales. The optional information boxes were placed to control the survey 
results in case of need. Sales price (MVP) was not kept optional since it was 
selected as one of the main component of the formula. 
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Scopes of the questions are listed such respectively; Novelty of patent, Inventive activity, 
Legal status of patent/project, Infrangibility (Difficulty to invent around), Breadth of patent, 
Publication of patent and parties willing to buy the project/patent, Remaining lifetime of 
patent, Geographical coverage of patent, Status of commercialization, Identification of 
infringing copy products, Life expectancy, Portfolio position of patent and Status of 
production. 
 
Some of the questions had already been designed by IPscore®‟s producers. Thus, 1st, 3rd, 
9th, 10th, 13th questions were adopted from IPscore®. The adopted questions were 
improved with little modifications. And also, weighing questions were added to each 
question in order to determine weight of the questions fairly. Thus, weight of each question 
was going to be determined by the participants (IP market). This also means that participants 
(IP market) determine significance of each patent value indicator via this survey. 
Determining fair weight for each question is essential for developing the formula as well. 
Hereby, questionnaire was adjusted to be compatible with the possible (rough) formula 
(patent value estimator). Third question of the questionnaire is shown in figure 8 as an 
example. 
 
 
 
Figure 8. The figure indicates typical structure of a question from the questionnaire. 
It consists of a main question with multiple answers and an additional weighing 
question to the main question with its choices (0-10). 
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3.3 Formula for patent valuation 
In the beginning of February 2011, the questionnaire was prepared. Then, a mathematical 
formula was developed depending on the questionnaire. The target group of the survey was 
patentees/inventors who have had already sold or bought a patent in biotechnology field. 
Depending on the answers to the questionnaire, it was planned to make a linear regression 
analysis to obtain required coefficient of the formula for the further estimations of monetary 
value of the patents. Regression analysis is a statistical tool for the investigation of 
relationships between variables. Usually, the investigator seeks to ascertain the causal effect 
of one variable upon another the effect of a price increase upon demand, for example, or the 
effect of changes in the money supply upon the inflation rate. To explore such issues, the 
investigator assembles data on the underlying variables of interest and employs regression to 
estimate the quantitative effect of the causal variables upon the variable that they influence. 
The investigator also typically assesses the “statistical significance” of the estimated 
relationships, that is, the degree of confidence that the true relationship is close to the 
estimated relationship (Sykes and Bhandari, 1997). 
 
The formula was designed algebraically linear instead of exponential, polynomial etc. to be 
able to normalize the variability amongst the further patent value estimations. (Model of the 
equation (why a linear equation) is discussed in discussion chapter with the details.) Thus, a 
basic possible linear equation was set up and named as Fatih‟s formula (FF) like below; 
 
MVP = FPV × ∑Sn +E 
 
MVP: Monetary Value of already sold/bought Patent (Sales Price) 
MVP will be answered by former or current patent owners who participate in the survey. 
According to linear regression modelling, MVP is the dependent variable 
 
FPV: FF Patent Valuator (Coefficient) 
Main purpose of the survey is to obtain a coefficient to make more patent value estimations. 
FPV is a dynamic coefficient; it would become stronger with higher number of the 
participation to the questionnaire. 
 
 
 39 
∑Sn: Sum of Scores from Each Answer to the Questions 
According to participants‟ answers to each question, each answer takes a pre-calculated 
score. And then all of the scores are summed. ‘∑Sn’ represents sum of the scores and ‘n’ 
represents number of each score obtained from answers to each different question. In this 
study ‘n’ is 13 since the questionnaire consists of 13 different questions. To state the matter 
more clear; ∑S13 = S1+S2+...S13. In this linear regression model, ∑Sn is the independent 
variable of the formula.  
 
Another aim of the survey is to determine a proper scoring method for each answer to the 
questionnaire. To find a fair scoring method for the formula, two-stage method was 
developed.  The first stage was to request an intellectual property rights (IPR) specialist to 
determine weight for each of multiple choices (answers) of each question in a proper way. 
Multiple answers of each question were weighed by Emeritus Professor Lars Monrad Krohn, 
he is a Norwegian engineer and entrepreneur. The determined weights for the choices of the 
questions are shown in table 3. 
 
Table 3. The table shows weights (determined by the IPR specialist) for each 
choice of each question correspondingly. For instance, weight of choice C of 
question 3 is 100. 
 
 
The second stage of developing a fair scoring method was to add a supplemental weighing 
question to each question, such as; „How inventive activity of your patent is important to you 
as concerning patent valuation? (Please choose one of the points from 0 to 10 below; 0 
being least important and 10 most important)‟. Thus, participants were supposed to select a 
point between 0-10 for each question. This would also help to determine significance of 
 
Questions 
Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 Q11 Q12 Q13 
C
h
o
ic
es
 
A 150 10 10 10 400 0 10 400 0 100 10 100 100 
B 300 100 50 400 500 400 300 600 300 300 100 200 300 
C 500 800 100 500 800 500 600 750 800 700 300 500 400 
D 900 1000 200 900 890 900 800 800 900 900 600 900 900 
E 1000 
 
500 1000 900 1000 900 900 1000 1000 900 1000 1000 
F 
  
700 
 
950 
 
1000 1000 
  
1000 
  G 
  
900 
 
1000 
        H 
  
1000 
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patent value determinants corresponding to the questions. In the end of the survey, average 
value of each answer to the weighing questions was going to be calculated separately. And 
then calculated average value for each question was going to be multiplied by pre-
determined weights of the choices according to the participants answer. The result of this 
multiplication gives scores (S) for each question.  
 
For example, assume that in the end of the survey; only five participants answered the 
questionnaire.  And they answered respectively 5,8,6,5 and 6 points to the weighing question 
of question #4. Then average value of those points is calculated as 6. And so, this average 
value is multiplied by each pre-determined weight of choice of the question #4 separately. 
According to the pre-determined weights on table 3, scores (S) for each choice (answer) of 
question #4 are calculated respectively;  
 Score for choice (A) = 6 × 10 = 60  
 Score for choice (B) = 6 × 400 = 2400 
 Score for choice (C) = 6 × 500 = 3000 
 Score for choice (D) = 6 × 900 = 5400 
 Score for choice (E) = 6 × 1000 = 6000 
 
According to this assumption, in future if any participant is supposed to answer the question 
#4 choosing choice (D), then score of the question #4 is taken as 5400 (S4 = 5400) for this 
patent valuation. Calculation of the score can be better understood with computation of the 
real data in chapter 4 (Results). 
 
E:  is called the error term, disturbance term, or noise. This variable captures all other factors 
which influence the dependent variable (MVP) other than the independent variable (∑Sn). 
The relationship between the error term and the independent variable, for example whether 
they are correlated is a crucial step in formulating a linear regression model, as it will 
determine the method to use for estimation.  
 
According to the results of the participations to the survey, relationship between the score 
and monetary patent value was going to be observed. In other words, regression analysis was 
going to help to answer the question „Does the monetary value of patent increase as the score 
increases?‟ 
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3.4 Survey Method 
Since required data for setting up the value estimator formula such as sales amount of 
patents, does not exist in on-line sources, it was needed to obtain those data by carry out a 
survey. In order to increase the number of participants to the survey as many as possible and 
to reach the different type of biotechnology companies in an easier way, it was decided to 
make an online survey. Hereby, a web domain, www.valuateyourip.com, was purchased. 
 
Questionnaire was redesigned and uploaded to the website by website designer in 
accordance with the survey. The website was constructed as password protected to prevent 
the accidental, undesired participations to the questionnaire as a consequence of the web 
searches. For instance, inappropriate people might make random searches on internet about 
patent valuation using related the keywords (such as „patent value‟, „patent valuation‟). 
Password of the website has been sent to the possible participants by e-mail.  
 
After logging with the password on the entrance page, the participants were supposed to see 
the introduction page. And from there they could answer the questions on the questionnaire 
page after clicking on „Clik here to start questionnarie‟ line. Following pictures (Figure 9, 
10, 11) show which pages the participant would see in order. 
 
Figure 9. The figure shows access page of the website. Participants type the 
password into the box and click on ‘’Log inn’’ button then pass to the next page 
(introduction page.) 
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 Figure 10. View of the introduction page on the web page. Participants are briefly informed 
 about the questionnaire and the project on this page. 
 
Figure 11. The figure is a sample view from questionnaire page. 
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An online database was constructed by the web designer. The database were connected to 
the questionnaire and tested like in figure 12. 
 
 
 
Figure 12.  The figure is a view from tested database of the website. Participant’s 
answers to each question and corresponding points (weights) to each question are 
shown in this figure. 
 
3.4.1 Trial Survey 
Target group of the survey was around thousand different biotechnology companies. In the 
beginning of the survey, emailing process was launched with sending simple emails (without 
any details of the study) including the web address and the password. The emails were sent 
to 20 different biotechnology companies to be able to see whether they have any objection 
about any question on the website. It was also supposed to have some feedbacks from the 
participants about the study. And as expected, some feedbacks related to the some questions 
were received. For instance, some of the companies didn‟t want to give their company 
names, one of them did not want to give patent number, another one did not want to mention 
date of sale and those 20 companies did not participate in the survey either. In the earliest 
version of the website, all the questions were supposed to be answered by the participant to 
be able submit the questionnaire. If any question was skipped, participant could not submit 
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the questionnaire. According to the initial feedbacks, first three identifier questions were 
made optional as shown in Appendix 1. 
3.5 Marketing of the Questionnaire 
After completing the necessary changes on the website, a very brief and informative email 
(Appendix 2) was prepared for direct mail to the target companies. This email was sent to 
around thousand different biotechnology companies (Appendix 3) by evaluating profiles of 
the companies in accordance with their IPR activities. Web address of the questionnaire and 
required password (to access the website) were given in the email. The concerned personnel 
of the companies were requested to participate in the survey via email. In case of their 
involvement in the project, it was promised that the website would be an open source for 
valuation of their patents and patent applications in future without any demand.  
 
The survey study took more than two months. During the survey, social media websites were 
also used to advertise the website on the relevant groups‟ pages of the social networks. In 
addition, direct phone calls and meetings were done with people who could contribute to the 
project. A high participation to survey was targeted to guarantee a stronger coefficient for 
the further patent value estimations. 
 
Unfortunately, level of participation to the survey was very low in the end of survey period. 
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4. Results 
In this section, even though very low number of the participation to the survey was obtained, 
regression analysis is applied on available data in order to explain how to calculate the 
coefficient (FPV) and how the model (FF model) works. 
4.1 Respondents to the questionnaire 
In the end of two months survey period, only 4 participants answered the questionnaire. 
Most of the companies replied the emails negatively. Some of the respondents even didn‟t 
want to participate in project without any excuse. Another group of the repliers did not 
contribute to the survey because of their confidentiality policy. And there were a low number 
of the repliers that have not had any patent/technology sales activities yet. In other, words 
emailing method was not successful.  
4.2 Evaluation of the Results 
As mentioned previously, four companies participated in the survey. Names of the 
participants are not given here because of the confidentiality agreement. In the study, 
representative names were used to symbolize names of the participant companies. 
Representative names are „company 1, company 2, company 3 and company 4. Most of the 
participants answered all required questions for the value estimation, while one has not 
answered the sales price of the patent.  Each of the participants contributed to the project 
with one patent. Their answers to the main questions are shown in the table 4 and answers to 
the weighing questions are shown in the table 5. 
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 Table 5. The table shows the participants’ answers to the weighing questions. W is 
the abbreviation of ‘Weighing question’ and A is the abbreviation of the ‘Answer’ to 
the weighing question. For instance, answer of company 3 to 5
th
 weighing question 
is 7(shaded with green on the table). Bottom row of the table shows the average of 
answers to the weighing questions. For weighing question #1, average value is 
calculated as 6, 75 (shaded with blue). Calculation of the average value for 
weighing question 1is (6+9+7+5) ÷ 4 =6, 75 
 
 
 
Table 4. The table indicates results of the survey, which are answers (given by the 
participants) to the main questions. For example, table shows that question 4 was 
answered with choice C (shaded with green) by ’Company 2’.  * Q is the 
abbreviation of ‘Question’ and * A is abbreviation of ‘Answer’.   
 
Questions  
Sales Price  *Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 Q11 Q12 Q13 
A
n
sw
er
s 
*A of 
Company 1 1.000.000 ($)  
 
A 
 
B 
 
G 
 
B 
 
A 
 
D 
 
D 
 
E 
 
F 
 
C 
 
F 
 
C 
 
F 
A of 
Company 2 Not answered B B F C A D B C C D F D D 
A of 
Company 3 50.000.000 ($) E C D C B B F D D B F D B 
A of 
Company 4 50.000. 000 ($) C C E C B D F F E D F A A 
 
Weighing Questions 
*W1 W2 W3 W4 W5 W6 W7 W8 W9 W10 W11 W12 W13 
A
n
sw
er
s *A of Company 1 6 7 10 10 8 7 9 9 10 8 9 10 10 
A of Company 2 9 9 8 7 3 5 10 8 9 8 8 8 6 
A of Company 3 7 8 7 8 7 8 9 9 9 8 8 8 9 
A of Company 4 5 5 9 8 6 8 8 9 10 8 8 6 9 
Average weight 
    for each question 6,75 7,25 8,5 8,25 6 7 9 8,75 9,5 8 8,25 8 8,5 
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4.2.1 Calculation of Scores for Each Choice (Answer) of each Question 
By determining a fair scoring method, it was also aimed to achieve converting quality of 
each value determinant of patent into quantity. In this study, quality of patent is determined 
by score which was derived from answers to the questionnaire.  Hereby, to be able to 
calculate coefficient (FPV) of the formula, firstly it was required to calculate precise scores 
(S) for each answer (choice) according to results of the survey. In this point, average weight 
for each question (shown in table 5) and pre-determined weights for each choice (shown in 
table 3) in the questionnaire are multiplied. Results of the multiplications and an example 
about scoring system are given in table 6. 
 
Table 6. The table shows the calculated score for each answer placed under each 
question.Q1 represents question 1 and A, B...H represent choices of the questions. 
For example, assume that an inventor valuates his/her patent in future using FF 
method. If the inventor answers the question #9 choosing the choice C (shaded with 
purple), score (S9) for the question #9 will be 7600 in that valuation. 7600 was 
calculated multiplication of 9, 5 (see table 5; the intersecting box of bottom row and 
W9 column) and 800 (see table 3; pre-determined weight for choice C of question 
number 9) 
SCORES TO BE USED FOR FURTHER PATENT VALUE ESTIMATIONS 
 
Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 Q11 Q12 Q13 
Sc
o
re
s 
fo
r 
th
e 
ch
o
ic
es
 o
f 
ea
ch
 
co
rr
es
p
o
n
d
in
g 
q
u
es
ti
o
n
 
A 1012,5 72,5 85 82,5 2400 0 90 3500 0 800 82,5 800 850 
B 2025 725 425 3300 3000 2800 2700 5250 2850 2400 825 1600 2550 
C 3375 5800 850 4125 4800 3500 5400 6563 7600 5600 2475 4000 3400 
D 6075 7250 1700 7425 5340 6300 7200 7000 8550 7200 7425 7200 7650 
E 6750 
 
4250 8250 5400 7000 8100 7875 9500 8000 8250 8000 8500 
F 
  
5950 
 
5700 
 
9000 8750 
     G 
  
7650 
 
6000 
        H 
  
8500 
           
4.2.2 Scoring the Results from each Participant 
Since „Company 2‟ did not answer the sales value question on the questionnaire as 
mentioned in section 4.2, there was no need to score for answers of Company 2.  
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Answers of the other three participants are already shown in table 3. Corresponding scores to 
answers of those three participants (Company 1, Company 3 and Company 4) are shown in 
table 7. 
 
Table 7. The table is combined version of table 4 and table 6. Corresponding scores 
to the answers given by the participants (companies) are shown in the table. 
 
Corresponding scores to answers given 
by the particiants  
Company 1 Company3 Company4 
S1: Score for answer to Question #1  1012,5 6750 3375 
S2: Score for answer to Question #2 725 5800 5800 
S3: Score for answer to Question #3 7650 1700 4250 
S4: Score for answer to Question #4 3300 4125 4125 
S5: Score for answer to Question #5 2400 3000 3000 
S6: Score for answer to Question #6 6300 2800 6300 
S7: Score for answer to Question #7 7200 9000 9000 
S8: Score for answer to Question #8 7875 7000 8750 
S9: Score for answer to Question #9 9500 8550 9500 
S10: Score for answer to Question #10 5600 2400 7200 
S11: Score for answer to Question #11 8250 8250 8250 
S12: Score for answer to Question #12 4000 7200 800 
S13: Score for answer to Question #13 8500 2550 8500 
∑S13  : Sum of the scores 72312,5 69125 78850 
 
 
4.2.3 Calculation of the Coefficient 
Sum of the scores (∑S13:  independent variables of the equation) and patent sales values 
(MVP: dependent variable) of the participants were placed on a Microsoft office excel sheet 
like in table 8. 
 
Table 8. Monetary value of participants’ patents (dependent variable) and sum of 
the scores (corresponding to the participants answers are given in the table. 
 ∑S13 MVP 
Company 1 72312,5 1.000.000$ 
Company3 69125 50.000.000$ 
Company4 78850 50.000.000$ 
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Using Microsoft office excels, regression analysis was carried out with the data that is shown 
in table 8. Summary of the regression analysis is shown in table 9 and figure 13 shows the 
relation between ∑S13 and MVP. 
 
Table 9. The table shows the summary of regression analysis of the ∑S13 and MVP 
($) (see table 8) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 13. The figure shows the regression line between two parameters which are 
MVP ($) and ∑S13 (see table 8). 
 
As a  result of the regression analysis via Microsoft office excel, an equation was obtained 
like below;  
y = 1113.1x - 5×107 
 
In this equation, y represents MVP and x represents ∑S13 . The coefficient (FPV) for further 
patent value estimations is 1113.1  and E is -5×107. Hereby, according to result of the 
survey, FF (Fatih‟s Formula) is adjusted to a new version; MVP = 1113.1x × ∑S13 - 5×10
7
. 
Regression Statistics 
Multiple R 
 
0.195061279 
R Square 
 
0.038048902 
Adjusted R Square 
 
-0.9239022 
Standard Error 
 
6876.613447 
Observations 
 
3 
 
P-value Standard Error 
Intercept 0.06161762 7017.654157 
X Variable 1 0.875018852 171.8795317 
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4.2.4 Summary of the results 
According to the results (shown in table 9), effect of the independent variable on the 
dependent variable is statistically significant, because the P value (P= 0. 06161762, shown 
in table 9) is higher than 0, 05. In addition, R Square was calculated as 0.038048902 (shown 
in table 9), which means that barely %3.8 of variation in the dependent variable (MVP: 
Monetary value of patent) is explained by variation in the independent variable. Therefore, 
as concerning both P value and R Square, it can be concluded that estimates on further 
patent value, which would be carried out via FF model, would be very weak. (In figure 13, 
regression between MVP and ∑S13 is visualized.)  
 
How to Use the Current Results for the Further Estimations 
For instance, assume that a patentee answers the questionnaire and calculates sum of the 
scores in accordance with each answer about the subject patent using the table 6. Then the 
only thing he should do to put the sum of the scores (∑S13) value in relevant place on the 
formula (MVP = 1113, 1 × ∑S13 +1414650) and calculate the estimated monetary value of 
subject patent. 
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5. Discussion 
Obviously, statistical evaluation of the results is not sufficient to prove exact validity of the 
current model (FF model) since number of the participants were very low. However, it is still 
possible to estimate further patent value using the formula. As mentioned before, these 
statistical calculations were carried out solely to explain how FF model was constructed and 
how it works even though very low number of participation to the survey. 
Why the Formula was Set Up Linear  
The goal of setting up linear equation via linear regression analysis is to adjust the values of 
slope and intercept in order to find the line that best predicts dependent variable (MVP) from 
independent variable(s). More precisely, the rationale of regression is to minimize the sum of 
the squares of the vertical distances of the points from regression line, which is obtained 
from regression between monetary value of patent (MVP), and sum of the scores (∑S13). In 
this way FF model was simplified and so further estimations via FF model are optimized.  
Why  Simple Linear Regression Analysis was Carried Out 
Unfortunately, low number of participation to the survey affected construction of the 
formula negatively. This level of the participation caused formula to be constructed as 
simple linear equation via simple linear regression analysis. If there were high number of 
participation of the survey, the best way to develop a formula was to do multiple linear 
regression analysis instead of simple linear regression analysis. Therefore, best way of 
evaluating results of the survey was to make simple linear regression analysis in order to 
make logical comments on summary of the analysis. 
 
To be able to carry out simple linear regression analysis, there must be two variables 
(independent and dependent). According to FF model, one of the variables is MVP 
(dependent variable: monetary value of patent) and the other one is ∑S13 (independent 
variable: sum of the scores).  Therefore, it was required to sum up the scores which are 
obtained from participant‟s answers to each question. Hereby, number of the independent 
variables (individual scores from answers to the questionnaire) was reduced from 13 to 1 by 
summing up scores (S1-S13) of answers to the questionnaire. This enabled the survey results 
to be compatible for simple linear regression analysis. And then explanatory comments on 
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summary of simple linear regression analysis supported the thesis. Hereby, the thesis was 
supported with explanatory comments on results of simple linear regression analysis. 
Multiple Regression Analysis in case of High Number of Participation 
If there were high number of participation to the survey, multiple regression analysis could 
be carried out with those results instead of linear regression analysis. A multiple linear 
regression analysis is carried out to predict the values of a dependent variable, Y, given a set 
of p explanatory variables: independent variables (X1, X2... Xp). In other words, multiple 
regression analysis enables to predict value of dependent variable by using more than one 
independent variable. For instance, model for estimating amount of heating oil used for a 
single family home in the month of January is based on average temperature and amount of 
insulation in inches. According to this model, amount of oil used for heating is dependent 
variable and average temperature and amount of insulation are independent variables (2007).  
 
For FF model, to carry out multiple regression analysis, each score from each answer would 
be used as independent variable individually. So, there would be 13 different independent 
variables (scores obtained from answers to the corresponding questions). This means that 
there will be 13 different coefficients for each score (S1...S13) instead of only one (FPV) for 
sum of scores (∑S13) as well. Each of 13 different scores represents individual effecting 
degree of each value determinants to value of subject patent. And there would be one 
dependent variable which is monetary value of patent. So, possible formulation which can be 
generated via multiple regression analysis would be like in following; 
MVP = FPV1×S1+ FPV2×S2 + FPV3×S3... + FPV13×S13+ B* 
*B is constant which is generetad by multiple regression analysis of the data 
 
So, by using multiple linear regression analysis, it is possible to observe how qualities of the 
value determinants affect monetary value of patent quantitatively in combination and to 
make better estimations on monetary value of patent. 
What was Succeeded 
In spite of low number of participation to the survey, the current participants (company 1- 4) 
contributed to determining weigh of each value determinant of patent individually. There 
were very close and same answers from the participants, to the weighing questions (see table 
5). Hereby, reliability of the scoring method was proved to some degree. It was possible to 
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obtain better scores for each answer of each individual question. In this study, scoring 
method was developed at two stages (mentioned in section 3.3). At the first stage, scores for 
each answer of each individual question are determined by an IPR specialist. Then, at the 
second stage pre-determined scores for answers of each question are multiplied by the 
average weight (see table 5) of corresponding weighing question. 
Upper and Lower Estimation Limits: Estimation Interval 
Only drawback of the formula is that further estimations will always be made within an 
interval depending on results of the survey. This interval is determined by the results which 
are obtained from scoring (participants‟ answers to the weighing questions) and FPV is 
generated by regression analysis. 
 
The scoring system of the questionnaire is limited by itself. Because, scoring system of FF 
model was developed by using pre-determined scores (by the IPR specialist) and post-
determined scores (by participants to the survey). Pre-determined scores range from 0 to 
1000 and post-determined scores range from 0 to 10. Additionally, dependent variable in the 
regression analysis (MVP) is given by the participants, and then MVP will always have 
lower and upper limits within data-set. According to the limits of MVP and the scoring 
system; FVP, which is generated from regression analysis of MVP and the ∑S13, will 
consequently have upper and lower limits. 
Adjusting MVP(Sales Price: Monetary Vallue of Patent) to Present 
While evaluating results of the survey, there was no need to adjust MVP to present since 
there was low number of participation to the survey and sales dates of the participants‟ 
patents were very close to each other and present year. However, if number of participants to 
the survey was high, then MVP can be adjusted to present. For instance, assume that a 
participant answers the questionnaire and sales price of subject patent is 10 million 
American Dollars and sales year of the patent is 2005. Then, multiplying MVP of 2005 with 
cumulative inflation rate for 6 years (from 2005 to 2011) MVP of 2005 is adjusted to present 
year. 
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What can be improved 
As pointed out in the discussion part, best way of evaluating results of the survey is multiple 
linear regression analysis. To be able to perform multiple linear regression analysis and to 
summarize the result of the analysis reasonably, there must be high number of sample. In 
other words, number of patentees must be increased. It is possible to increase the level of 
participation through contribution from patent offices like EPO and USPTO in a PhD study 
and big biotechnology companies such as pharmaceutical companies. If they contribute to 
increase number of participants to the survey, stronger coefficients for the formula (FF) 
would be generated via multiple regression analysis. 
 
It is also possible to improve the questionnaire by adding some more questions relevant with 
patent value. Especially, scoring method can be improved with additional weighing 
questions. In the scoring, score for each individual answer was calculated from 
multiplication of pre-determined and post-determined scores. Pre-determined scores were 
determined by an IPR specialist. This method was fair to some degree; however, it can be 
improved. Instead of benefiting from an IPR specialist about scoring, it can be asked directly 
to participants to weigh each individual answer of the questionnaire. Then, it is possible to 
place additional weighing questions next to each individual answer, similar to the current 
weighing questions. 
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6. Conclusion 
A multidisciplinary study was carried out to achieve the goals of the dissertation.  
Specifically, the objective of developing a method (FF) in the project was succeeded to some 
degree. This project was based on a survey and since there were low number of interest in 
the survey, FF method could not be developed fairly. Even though the specific aim of the 
thesis could not be achieved completely, while sub-aims of the thesis were achieved fairly, 
which were preparation of a questionnaire by converting most remarkable patent value 
determinants to the questions, performing a survey by using this questionnaire, developing a 
fair scoring method on the questionnaire for further estimations on patent value, finding out 
other possible mathematical formulations for further estimations and observing weight of the 
value determinants with the survey study. 
 
To achieve the goals mentioned above, firstly literature search was done. Hereby, notion of 
patent value was comprehended. Current valuation methods for estimating monetary value of 
patent were learned. Patenting process and value determinants of patent were investigated. 
By choosing most emphasized determinants of patent value from the literature and 
converting them to questions, a questionnaire was prepared. This questionnaire was prepared 
for the purpose of developing a quick method which can estimate economic value of core 
business patents. Then a website was designed for purpose of a survey. To convince as 
patentees many as possible about participation in the survey, many different strategies were 
carried out such as; e-mailing, promotion (promising use of the method free of charge), 
phone calls and meetings. However, desired number of participants could not be reached. 
Despite low number of the participation, functionality of the method and alternative methods 
were explained by using the available data from the present participants. The method helped 
to observe effects of the value determinants on patent value during patenting process. 
 
As a result, the project has been concluded with low level of participation. However, most of 
the required subjects to develop a method for estimation of monetary value of patent were 
very well comprehended. 
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Appendices 
Appendix 1 
Questionnaire for patent valuation 
 
 
Please write your company name into the box (optional):  
 
 
Please write your patent number into the box (optional):  
  
 
Date of sale (year, optional):  
  
 
Sales price of your patent ($):  
  
 
1. - Novelty of patent  
 
What is the status of the invention as concerning its technological field?  
 
 A) Invention is an improvement on product of already existing technology 
and has a marginal effect in relation to existing technology 
 B) Invention is an improvement on product of already existing technology and 
has a significant effect in relation to existing technology 
 C) Invention is a unique product of existing technology and has a significant 
effect in relation to existing technology 
 D) Invention is a new technology and can create its own market 
 E) Invention is a new technology and applicable in many different industries 
 
How important is the novelty of your patent to the patent valuation? (Please 
choose one of the points from 0 to 10 below; 0 being least important and 10 most 
important)  
 
0 1 2 3 4 5 6 7 8 9 10 
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2. - Inventive activity  
 
How innovative is your product?  
 
 A) There are competitive products doing the same work 
 B) There are competitive products doing the same work but this one is more 
generative 
 C) There is no competitive product for the invention 
 D) Invention will have more value by developing complementary 
technologies 
 
How inventive activity of your patent is important to you as concerning patent 
valuation? (Please choose one of the points from 0 to 10 below; 0 being least 
important and 10 most important)  
 
0 1 2 3 4 5 6 7 8 9 10 
 
 
3. - Legal status of patent/project  
 
What is the legal status of patent/project?  
 
 A) Invention not yet disclosed to any patent attorney or patent office 
 B) Invention disclosed 
 C) Preliminary patentability search completed 
 D) Patent application not done yet 
 E) Patent application filed 
 F) Patent application filed and publicized 
 G) Patent granted 
 H) Patent granted and opposition period is over without any opposition  
 
How is the legal status of your patent important to you as concerning patent 
valuation? (Please choose one of the points from 0 to 10 below; 0 being least 
important and 10 most important)  
 
0 1 2 3 4 5 6 7 8 9 10 
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4. - Infrangibility (Difficulty to invent around)  
 
Is it easy to produce the imitated products?  
 
 A) Invention can be easily identified and produced 
 B) It is a complicated invention, it is needed to have high technology to 
produce copy products 
 C) It is a complicated invention that is difficult to produce copy products 
 D) It is extremely difficult to produce copy products 
 E) There is no other technology to produce copy product 
 
How is the infrangibility of your patent important to you as concerning patent 
valuation? (Please choose one of the points from 0 to 10 below; 0 being least 
important and 10 most important)  
 
0 1 2 3 4 5 6 7 8 9 10 
 
 
5. - Breadth of patent  
 
To what extend is the invention breadth?  
 
 A) It consists of more than 2 different technology 
 B) It consists of 2 to 6 different technology 
 C) It consists of 6 to 10 different technology 
 D) It consists of 10 to 14 different technology 
 E) It consists of 14 to 18 different technology 
 F) It consists of 15 to 22 different technology 
 G) It consists of more than 22 different technology 
 
How is the breadth of your patent important to you as concerning patent 
valuation? (Please choose one of the points from 0 to 10 below; 0 being least 
important and 10 most important)  
 
0 1 2 3 4 5 6 7 8 9 10 
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6. - Publication of patent and parties willing to buy the project/patent  
 
After disclosing your patent, who are willing to buy the product/patent?  
 
 A) There is no one willing to buy 
 B) There are few companies/investors willing to buy 
 C) Regional collaborators/partners of the relevant industry/technology are 
willing to buy 
 D) Global collaborators/partners of the relevant industry/ technology are 
willing to buy 
 E) Biggest collaborators/partners of the relevant industry/ technology is 
willing to buy 
 
How is the disclosure of your patent important to you as concerning patent 
valuation? (Please choose one of the points from 0 to 10 below; 0 being least 
important and 10 most important)  
 
0 1 2 3 4 5 6 7 8 9 10 
 
 
7. - Remaining lifetime of patent  
 
How long is left of your patent lifetime?  
 
 A) Less than 2 years 
 B) 2 to 4 years 
 C) 4 to 6 years 
 D) 6 to 9 years 
 E) 9 to 13 years 
 F) More than 13 years 
 
How is the remaining lifetime of your patent important to you as concerning 
patent valuation? (Please choose one of the points from 0 to 10 below; 0 being 
least important and 10 most important)  
 
0 1 2 3 4 5 6 7 8 9 10 
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8. - Geographical coverage of patent  
 
What is the range of patent geographical coverage?  
 
 A) Patent is filed only in one country 
 B) Patent is filed in JPO  
 C) Patent is filed in EPO  
 D) Patent is filed in USPTO  
 E) Patent is filed in triadic regions (EPO, JPO, and USPTO) 
 F) Patent is filed in almost all the countries having the relevant market 
 
How is the geographical coverage of your patent important to you as concerning 
patent valuation? (Please choose one of the points from 0 to 10 below; 0 being 
least important and 10 most important)  
 
0 1 2 3 4 5 6 7 8 9 10 
 
 
9. - Status of commercialization  
 
What are the marketing options?  
 
 A) There is no known market for the patented technology 
 B) The patented technology has not yet been targeted at a particular market 
 C) There is a well known market for the patented technology 
 D) There is a well known market and further, well-defined market options 
 E) There is a well known market and other tangible prominent markets 
 
How is the market of your patent important to you as concerning patent valuation? 
(Please choose one of the points from 0 to 10 below; 0 being least important and 
10 most important)  
 
0 1 2 3 4 5 6 7 8 9 10 
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10. - Identification of infringing copy products  
 
Is it easy to differentiate infringing copy products from the original?  
 
 A) It is not possible to differentiate the copy products  
 B) It is extremely difficult to differentiate copy products but not impossible 
 C) It is difficult to differentiate copy products 
 D) It is easy to differentiate copy products 
 E) It is extremely easy to differentiate copy products 
 
How is the identification of infringing copy products of your patented product 
important to you as concerning patent valuation? (Please choose one of the points 
from 0 to 10 below; 0 being least important and 10 most important)  
 
0 1 2 3 4 5 6 7 8 9 10 
 
 
11. - Life expectancy  
 
What is the life expectancy of the patented product/technology in the market?  
 
 A) Less than 1 year 
 B) 1-2 years 
 C) 4 years 
 D) 6 years 
 E) 10 years 
 F) More than 10 years 
 
How is the life expectancy of your patented product important to you as 
concerning patent valuation? (Please choose one of the points from 0 to 10 below; 
0 being least important and 10 most important)  
 
0 1 2 3 4 5 6 7 8 9 10 
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12. - Portfolio position of patent  
 
What is the position of Patent/Invention in your patent portfolio?  
 
 A) There is no patent portfolio yet. 
 B) Patent is the least important of the portfolio 
 C) Patent has moderate importance for the portfolio 
 D) Patent has a higher importance than several patents in the same portfolio 
 E) Patent is the most important patent of the portfolio 
 
How is the portfolio position of patent important for you as concerning patent 
valuation? (Please choose one of the points from 0 to 10 below; 0 being least 
important and 10 most important)  
 
0 1 2 3 4 5 6 7 8 9 10 
 
 
13. - Status of production  
 
To what extent has the invention been tested?  
 
 A) The invention has been tested in theory according to calculations 
 B) There have been experiments/ one-off tests 
 C) Production test has been completed 
 D) Production running  
 E) Full-scale production 
 
How is the production status of patented product important to you as concerning 
patent valuation? (Please choose one of the points from 0 to 10 below; 0 being 
least important and 10 most important)  
 
0 1 2 3 4 5 6 7 8 9 10 
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Submit form
 
 
Contact Info: 
M. Fatih Akaslan  
Phone: +47 99 86 98 18  
Email: info@valuateyourip.com 
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Appendix 2 
 
E-mail to Biotechnology Companies 
 
To whom it may concern 
 
Hello 
I'm master student, studying on commercialization of biotechnology at Hedmark University 
College / Norway. 
I'm currently studying on patent valuation in biotechnology field especially pharmaceutical 
industry. 
Briefly, I'm developing a new mathematical formula, which is based on a questionnaire, for 
monetary valuation of the patents. 
This questionnaire is for the patents which have already been sold or bought.  So, I should 
find patentees who have sold or bought their patents in last 15 years and I should kindly 
make the former or the current patent owner answer my questionnaire. 
In case you might have sold or bought any patent, here I have a website for the 
questionnaire, could you please visit following web link www.valuateyourip.com you need a 
password to get access the questionnaire, which is akademi1026 
I would be grateful, if you contribute to my project by answering my questionnaire online.  
To be able to perform a solid portfolio management of patents and patent applications, 
obtaining an estimate of economic value is necessary. In the end of this study I will have an 
open web source for the patentees who want to estimate monetary value of their patents. 
This study does not compromise the disclosure of any confidential information. I hope you 
would like to contribute to my project. 
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If you have any question about the project, please contact me. 
Best regards, 
M. Fatih AKASLAN 
Skolegata HiH  BioHus 313 
2315 Hamar Norway 
Mobile +4799869818  (11.00h-18.00h UTC+01:00) 
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Appendix 3 
List of Target Group of the Survey (Websites of the Biotechnology 
Companies) 
http://alphascience.de 
http://apogenix.com/ 
http://aquabiotechnology.com 
http://atgenglobal.com 
http://bifido.com 
http://bionamics.de  
http://bionutrigen.com/ 
http://biosensor.se/ 
http://biospectrum.com 
http://biostorage.com  
http://bsvbio.de   
http://bta-international.de 
http://cbnbiotech.hubweb.net 
http://chr-hansen.de 
http://dsmbio.cafe24.com 
http://ebioline.en.ecplaza.net 
http://ekvv.uni-
bielefeld.de/pers_publ/publ/PersonDetail.j
sp?personId=161617 
http://en.cetotec.com 
http://en.subitec.com 
http://endotherm-lsm.com/  
http://eng.cjcheiljedang.com 
http://everestbiotech.com  
http://genocheck.com 
http://gpbb.de 
http://investor.dionex.com 
http://oncophyta.org 
http://piramalhealthcare.com/  
http://sciencepark.ki.se/node/140 
http://shop.allelebiotech.com   
http://trd.as/wp02/ 
http://wilex.de 
http://www.3b-pharma.com 
http://www.4base-lab.de/index_3.htm 
http://www.4sc.de 
http://www.a2m-pharma.com  
http://www.aak-diagnostik.de/  
http://www.abdserotec.com 
http://www.abenzymes.com 
http://www.abexome.com/  
http://www.abigo.se 
http://www.abitep.de/en/Contact.php 
http://www.absorber.se  
http://www.abxis.com 
http://www.acceleratorab.se 
http://www.accelero-bioanalytics.com/ 
http://www.accuramed.de 
http://www.acino-pharma.com 
http://www.acrossbarriers.de 
http://www.actar.se/about-actar.aspx 
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http://www.activaero.de 
http://www.activebiotech.com 
http://www.adapt-localization.com 
http://www.aditusmedical.com 
http://www.adnagen.com/ 
http://www.advalytix.com 
http://www.aerocrine.com 
http://www.aeschemunex.com 
http://www.aesku.com 
http://www.aet.eu 
http://www.affectis.com/about-us 
http://www.affibody.com 
http://www.affimed.com 
http://www.affitech.com/ 
http://www.agennix.com/ 
http://www.agon.de/en/philosophy/ 
http://www.agrisera.com 
http://www.agroprotect.com/english.html 
http://www.ahn-bio.de 
http://www.aicuris.com 
http://www.aid-diagnostika.com 
http://www.aj-ebiochip.com 
http://www.akampion.com 
http://www.alcedo-biotech.com 
http://www.alcon.com 
http://www.alcon-pharma.de/ 
http://www.alere.de 
http://www.algeta.com/ 
http://www.algonet.se/~binab/ 
http://www.allergopharma.de 
http://www.alligatorbioscience.com 
http://www.almagest.se 
http://www.alphalytik.de 
http://www.alpharma.com/index.cfm 
http://www.alrise.de/ 
http://www.amedic.se/pf.html 
http://www.amgen.com 
http://www.amgen.de 
http://www.amino.de 
http://www.am-labor.de  
http://www.amocol.com 
http://www.amodia.com 
http://www.amplab.de/ 
http://www.amsilk.com 
http://www.anagnostec.eu/ 
http://www.analytica.se 
http://www.analytical-services.com 
http://www.anamar.com/1/en/home/home.
php 
http://www.anatomica.se/index.asp 
http://www.anatox.de 
http://www.anbicc.de/ 
http://www.angio-lab.co.kr/ 
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http://www.anmedic.se/eng_index.php 
http://www.anm-medical.com 
http://www.anoxymer.de 
http://www.anterio.com 
http://www.antikoerper-biologo.de   
http://www.antisense-pharma.com 
http://www.anygen.co.krwww/portfolio/en
_index_04.php 
http://www.apara-bioscience.de/ 
http://www.apimeds.com/ 
http://www.apogene-gmbh.de 
http://www.aquazosta.de/ 
http://www.argosbiotech.de 
http://www.artemis-ag.com/ 
http://www.artemis-ag.com/ 
http://www.artes-biotechnology.com 
http://www.asa-enzyme.de/ 
http://www.asca-berlin.de 
http://www.ascendispharma.com/about 
http://www.ascenion.de/ 
http://www.ascenion.de/en/aboutus.html 
http://www.astareal.com 
http://www.astrabiotech.de/eng/about/ 
http://www.attana.com 
http://www.atto-tec.com/ 
http://www.aurigene.com 
http://www.aurigon.de/ 
http://www.autodisplay-biotech.com 
http://www.autotissue.de 
http://www.avaris.se/ 
http://www.averionintl.com 
http://www.averionintl.com/ 
http://www.avesthagen.com 
http://www.avesthagen.com 
http://www.avestin.com/ 
http://www.avivasysbio.com 
http://www.axiogenesis.com 
http://www.axis-shield.com 
http://www.azigroup.co.kr 
http://www.bag-germany.com 
http://www.bavarian-
nordic.com/about.aspx 
http://www.bayer.com/ 
http://www.baypat.de/de/impressum.html 
http://www.bbraun.de 
http://www.bbt-biotech.de 
http://www.bc-diagnostics.com 
http://www.bddcdrd.com 
http://www.bec-biotechnic.de/ 
http://www.beckmancoulter.de 
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http://www.beiersdorf.de 
http://www.beiersdorf.se 
http://www.belach.se 
http://www.bergenstrahle.se/ 
http://www.berlinbiotechpark.de/en/Conta
ct.html 
http://www.berlin-chemie.com/ 
http://www.berninaplus.de/contact.htm 
http://www.berthold-ds.com 
http://www.bestechworld.com 
http://www.beuth-
hochschule.de/impressum/ 
http://www.bharatserums.com 
http://www.biaffin.com/ 
http://www.bibitec.de/smail.php 
http://www.bicoll-group.com/ 
http://www.bideco.com/flash/index1.html 
http://www.biedermann.com 
http://www.big21c.co.kr 
http://www.bilatec.com/pages/struktur_e.h
tml 
http://www.binder-associates.de 
 http://www.bioanalyt.com  
http://www.bioanalytic.de 
http://www.bioanalytical-solutions.com 
http://www.bioassay-online.de   
http://www.biocampuscologne.de/  
http://www.biocat.com/contact 
http://www.biocell.de 
http://www.biocentiv.com 
http://www.biocheck.de/ 
http://www.biochem.de  
http://www.biochemagrar.de  
http://www.biochrom.de  
http://www.bio-city-leipzig.de 
http://www.biocon.com 
http://www.bioconcept.ch  
http://www.bioconweb.de  
http://www.biofluidix.com 
http://www.bioforsk.no  
http://www.biofrontera.com 
http://www.biogaia.com 
http://www.biogal.co.il  
http://www.bio-gate.de 
http://www.biogenerix.com/index1.html 
http://www.biogenes.de/ 
http://www.biogenidec.de 
http://www.biogenidec.se/ 
http://www.bioglobe.net   
http://www.bioinvent.com/ 
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http://www.biokjemisk.com 
http://www.biolabels.com 
http://www.biolandkorea.com 
http://www.bioleaders.co.kr 
http://www.biolight.se/ 
http://www.biolin.se/ 
http://www.bioline.com 
http://www.biolink.no 
http://www.biolog.de 
http://www.biolog-heppe.de 
http://www.biologicale.com 
http://www.biologis.com 
http://www.bio-
mar.de/biomar_uk/index_prod.html 
http://www.biomecca.co.kr 
http://www.biomers.net 
http://www.biometec.de 
http://www.biometra.com 
http://www.biomeva.com 
http://www.biomex.de   
http://www.biomist.co.kr 
http://www.biomolex.com/ 
http://www.bionas-discovery.com 
http://www.bio-nord.de 
http://www.biophausia.se/ 
http://www.bioportfolio.com 
http://www.biorefinery.de/frameset.htm 
http://www.bioregio-stern.de/en/node/10 
http://www.bioriver.de   
http://www.bio-security.de 
http://www.biosense.de  
http://www.biosense.no 
http://www.biosentrum.no/index.htm 
http://www.bioservice.com 
http://www.bioskin.de  
http://www.bioskintech.co.kr/ 
http://www.biosolveit.de   
http://www.biosphings.com  
http://www.biospring.de  
http://www.bios-schoenow.de  
http://www.biostep.de   
http://www.biosyn.de   
http://www.bio-synectics.com 
http://www.biosyntan.de  
http://www.biosys.de/en/imprint.html 
http://www.biotage.com/ 
http://www.biotec.no 
http://www.biotecmarin.de 
http://www.biotec-rhein-erft.de 
http://www.biotecsistemi.it 
http://www.biotek.com 
http://www.biotestlab.de 
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http://www.biotesys.de 
http://www.biotez.de  
http://www.biothema.com/ 
http://www.biotissue.de   
http://www.biotop.de 
http://www.biotrend.com 
http://www.biotronik.com   
http://www.biotronix.de  
http://www.biotype.de  
http://www.biovativ.de  
http://www.bioversal.de   
http://www.biovision-biomaterial.de 
http://www.bioworlde.com   
http://www.bioworx.de 
http://www.bitmos.de/ 
http://www.bitop.de 
http://www.bls-germany.com 
http://www.bmglabtech.com 
http://www.bm-group.at 
http://www.bms.com/ 
http://www.bmz-do.de  
http://www.bncbio.com/ 
http://www.boehringer-ingelheim.com 
http://www.boehringer-ingelheim.de 
http://www.boehringer-ingelheim.se/ 
http://www.boule.se/ 
http://www.bpi.de 
http://www.brain-biotech.de 
http://www.brand.de  
http://www.brandel.com 
http://www.breas.com 
http://www.bruker-biospin.com  
http://www.brynaarflot.com  
http://www.bst-biosensor.de  
http://www.btgin.com/ 
http://www.bw-i.de 
http://www.cabion.de  
http://www.cair-biosciences.de/ 
http://www.caliperls.com  
http://www.camag.com  
http://www.cambrex.com/   
http://www.cambrex.com/ 
http://www.campro.eu/index1.html 
http://www.campus-micro-
technologies.de/4_1.htm 
http://www.camurus.com/ 
http://www.canadacomposting.com  
http://www.candor-bioscience.de  
http://www.can-hamburg.de  
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http://www.caprotec.com 
http://www.caregen.co.kr 
http://www.carlroth.com  
http://www.carpegen.de 
http://www.carus-it.com 
http://www.cat-online.com   
http://www.cavidi.se/ 
http://www.cavira.de 
http://www.cedarlanelabs.com 
http://www.celares.com 
http://www.cellavision.se 
http://www.cellcultureservice.com 
http://www.cellectricon.se 
http://www.cellmed.com 
http://www.cellpharm.com 
http://www.cellserve.de 
http://www.cellsystems.de/ 
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